Msi-H/Dmmr

Dr. Overman Discusses Nivolumab in Patients With dMMR/MSI H mCRC

Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRC

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

What is microsatellite instability or MSI?

IOU Youtube: Linking MSI-H/dMMR to IO research

Dig Deeper Into Immuno-Oncology Research

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

Immunotherapy in MSI-H/dMMR mCRC: first-line options and dual checkpoint inhibition insights

Analysis of HLA gene expression in dMMR/MSI-H, ICI-resistant CRC

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal c...

Current and future trends in immunotherapy for MSI-H colorectal cancer

CheckMate 8HW: first-line nivolumab plus ipilimumab in MSI-H/dMMR mCRC

Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRC

Targeted Oncology

The emerging role of ctDNA as a predicative marker in dMMR/MSI-H colorectal cancer

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

CheckMate-8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC